Safety and Efficacy of Subcutaneous Pasireotide in Patients With Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study

Frontiers in Endocrinology
Maria FleseriuPadiporn Limumpornpetch

Abstract

Introduction: The efficacy and safety of subcutaneous (sc) pasireotide have been evaluated in a Phase III trial. Here, we report safety and efficacy results from a multinational, expanded-access study of pasireotide sc in patients with Cushing's disease (CD) in a real-world setting (clinicaltrials.gov, identifier: NCT01582061). Methods: Adults with active CD previously untreated with pasireotide were enrolled; pasireotide sc was initiated at 600 μg twice daily (bid; EU countries) or 900 μg bid (non-EU countries; 600 μg bid in patients with impaired glucose metabolism). Pasireotide dose could be adjusted in 300 μg increments/decrements to a maximum of 900 μg bid or minimum of 300 μg bid for sustained urinary free cortisol (UFC) normalization/tolerability issues. Primary objective: document the safety of pasireotide sc in patients with CD. Key secondary objectives: assess the proportion of patients with mean UFC (mUFC) not exceeding the upper limit of normal (ULN) and changes from baseline in clinical signs/symptoms and quality of life (QoL) to weeks 12, 24, and 48. Results: One hundred and four patients received pasireotide: female, n = 84 (80.8%); median duration of pasireotide exposure, 25.1 weeks; median (range) baseline mUFC...Continue Reading

References

Apr 1, 1994·Clinical Endocrinology·J Etxabe, J A Vazquez
Apr 17, 2008·The Journal of Clinical Endocrinology and Metabolism·B M K BillerM Boscaro
Jul 22, 2008·Reviews in Endocrine & Metabolic Disorders·C de BruinL J Hofland
Oct 15, 2008·Journal of Endocrinological Investigation·R AttanasioE Ghigo
May 14, 2010·The New England Journal of Medicine·Richard A FeeldersSteven W Lamberts
Jan 21, 2012·Clinical Endocrinology·Annamaria ColaoRosario Pivonello
Mar 6, 2012·European Journal of Internal Medicine·D GraversenJ O L Jørgensen
Mar 9, 2012·The New England Journal of Medicine·Annamaria ColaoUNKNOWN Pasireotide B2305 Study Group
Apr 3, 2012·The Journal of Clinical Endocrinology and Metabolism·Maria FleseriuUNKNOWN SEISMIC Study Investigators
Jun 26, 2012·European Journal of Endocrinology·R A FeeldersA M Pereira
Mar 28, 2013·The Journal of Clinical Endocrinology and Metabolism·Olaf M DekkersHenrik Toft Sørensen
May 16, 2013·Journal of Neuro-oncology·Maria Fleseriu, Stephan Petersenn
Jan 30, 2014·The Journal of Clinical Endocrinology and Metabolism·Frederic CastinettiThierry Brue
May 26, 2015·Lancet·André LacroixLynnette K Nieman
Jun 13, 2015·Endocrine Reviews·Rosario PivonelloAnnamaria Colao
Jul 30, 2015·The Journal of Clinical Endocrinology and Metabolism·Lynnette K NiemanUNKNOWN Endocrine Society
Sep 10, 2015·The Journal of Clinical Endocrinology and Metabolism·Eleni DanielJohn Newell-Price
Apr 30, 2016·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·L TrementinoG Arnaldi
May 15, 2016·The Lancet. Diabetes & Endocrinology·Rosario PivonelloAnnamaria Colao
Sep 20, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Maria FleseriuUNKNOWN AACE Neuroendocrine and Pituitary Scientific Committee *
Oct 17, 2017·The Lancet. Diabetes & Endocrinology·André LacroixUNKNOWN Pasireotide G2304 Study Group
Feb 24, 2018·European Journal of Endocrinology·Jacques YoungUNKNOWN Compassionalte use Programme
May 15, 2018·Endocrinology and Metabolism Clinics of North America·Nicholas A Tritos, Beverly M K Biller
May 17, 2018·Frontiers in Endocrinology·Fabienne LangloisMaria Fleseriu

❮ Previous
Next ❯

Citations

Aug 20, 2020·Expert Review of Endocrinology & Metabolism·Cristina CapatinaMaria Fleseriu
Dec 29, 2020·Frontiers in Endocrinology·Rosario PivonelloAnnamaria Colao
Oct 5, 2021·Frontiers in Endocrinology·Julia Simões Corrêa GalendiVania Dos Santos Nunes Nogueira

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02060383

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.